TAVR Highlights: AI transforming care | Early treatment linked to key benefits | 'Highly concerning' Medicare trends

Advanced AI technologies are starting to play a bigger role in TAVR care, helping cardiologists plan ahead, make critical decisions and predict potential complications. Looking to the future, though, it is clear this is just the beginning. 

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Prosthesis-patient mismatch (PPM) is the phenomenon that occurs when the effective orifice area of a prosthetic heart valve isn’t adequately sized to meet a patient’s blood flow requirements. More is known today about PPM than ever before—but there is still so much to learn. 

The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.

Hospitals could be turning away high-risk heart patients to help their TAVR programs receive a higher ranking, according to new research published in JACC: Cardiovascular Interventions. 

Identifying the signs of severe aortic stenosis is typically a fairly straightforward process for cardiologists. In some cases, however, the patient’s symptoms present in a way that is outside of the norm. 

The Telltale system was designed to assist cardiologists when BASILICA is required prior to TAVR.

PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025.